BIO Convention to feature health and medical program.

Press Release Summary:



Scheduled for May 3-6, 2010 BIO International Convention will highlight latest scientific breakthroughs as well as policy and business development issues that impact drug discovery and development. Program includes historically popular tracks like Biomarkers and Drug Discovery and Development as well as new tracks for 2010 such as Delivery and Manufacturing of Biologics and Drugs, Global Drug Development and Marketing, and Innovations in Vaccines.



Original Press Release:



Biomarkers, Vaccines and Personalized Medicine Hot Topics at 2010 BIO International Convention



WASHINGTON, D.C. - The 2010 BIO International Convention will feature a robust health and medical program highlighting the latest scientific breakthroughs and policy and business development issues that impact drug discovery and development. Hosted by the Biotechnology Industry Organization, the Convention will be held May 3-6, 2010 in Chicago, Ill. at McCormick Place.

"This year's program showcases recent scientific advancements as well as the business and regulatory issues that allow our industry to extend and improve the health and lives of people around the globe," said Jim Greenwood, BIO's President and CEO. "The biotechnology community is constantly finding innovations that may someday treat or cure the most prevalent diseases, such as HIV/AIDS, cancer and malaria as well as numerous orphan diseases that affect smaller patient populations."

The program includes historically popular tracks like Biomarkers and Drug Discovery and Development as well as new tracks for 2010 such as Delivery & Manufacturing of Biologics & Drugs, Global Drug Development and Marketing and Innovations in Vaccines.

A sample of breakout sessions includes:

  • Therapeutic Cancer Vaccines - From Biological Complexity to Novel Patient Solutions

    Monday, May 3, 2:00 p.m. - 3:30 p.m.

    Speakers Include: Jens Oliver Funk, M.D., EMD Serono, Inc.; Wayne Godfrey
    BN ImmunoTherapeutics, Inc.; Jeffrey Schlom, Ph.D., National Cancer Institute; Helen Sabzevari, National Cancer Institute; Mark Frohlich, M.D., Dendreon

  • Commercialization of Biomarkers: From Discovery to Medical Diagnostics

    Monday, May 3, 4:00 p.m. - 5:30 p.m.

    Speakers include: Tim Clark, Piper Alderman; Christopher Boyle, Bio-Link; Michael Henry, Athena Diagnostics

  • Build or Buy? Strategic Choices in Biomanufacturing

    Tuesday, May 4, 2:00 p.m. - 3:30 p.m.

    Speakers Include: Anne Montgomery, BioProcess International; Laura Bush, Advanstar Communications; Parrish Galliher, M.S., Xcellerex, Inc; Steven Lee, Ph.D., A-Bio Pharma Pte Ltd.; Alain Pralong, Crucell NV; Eric Langer, Ph.D., BioPlan Associates, Inc.

  • Vaccines for the 21st Century

    Tuesday, May 4, 2:00 p.m. - 3:30 p.m.

    Speakers Include: Jeff Swarz, Ph.D., Caris and Company; Joe Shaw, Syntiron; Gavin Zealey, MBA, sanofi Pasteur; Vijay Samant, Ph.D.,Vical Inc.; Jan ter Meulen, M.D., Merck; James Jackson, Ph.D., Emergent BioSolutions, Inc.

  • It's Personal - Transforming Health Care through Personalized Medicine

    Tuesday, May 4, 4:00 p.m. - 5:30 p.m.

    Speakers Include: Edward Abrahams, Ph.D., Personalized Medicine Coalition; Linh Hoang, M.D., Life Technologies; Laura Shawver, Ph.D., The Clearity Foundation; Felix Frueh, MEDCO; Nicholas Dracapoli, Johnson & Johnson Pharmaceuticals

  • Pandemic Preparedness: Therapeutics Policy and Deployment

    Wednesday May 5, 10:00 a.m. - 11:30 a.m.

  • FDA Town Hall

    Wednesday, May 5, 10:00 a.m. - 11:30 a.m.

    Speakers Include: Douglas Throckmorton, M.D., U.S. Food and Drug Administration, Center for Drug Evaluation and Research; Karen Midthun, MD, U.S. Food and Drug Administration, Center for Biologics Evaluation and Research

    For detailed descriptions and a full program, please visit convention.bio.org/. Members of the media can register at convention.bio.org/media/.

    The annual BIO International Convention helps to support the association's programs and initiatives. BIO works throughout the year to create a policy environment that enables the industry to continue to fulfill its vision of bettering the world through biotechnology innovation.

    About BIO

    BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.
  • All Topics